Cover Image
市場調查報告書

多發性硬化症:流行病學的預測

Multiple Sclerosis - Epidemiology Forecast to 2027

出版商 DelveInsight Business Research LLP 商品編碼 601992
出版日期 內容資訊 英文 102 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
多發性硬化症:流行病學的預測 Multiple Sclerosis - Epidemiology Forecast to 2027
出版日期: 2018年03月01日 內容資訊: 英文 102 Pages
簡介

本報告提供全球多發性硬化症的流行病學的預測相關分析,提供疾病概要和目前治療手法/演算法,全球整體及主要國家 (美國·歐洲各國·日本) 的患病人數趨勢預測 (總計12年份),男女·各年齡·各子類型等詳細趨勢,今後的市場機會·醫藥品開發預測等相關調查。

第1章 簡介

第2章 多發性硬化症的流行病學:市場概要

  • 多發性硬化症的患者人口 (最新值·預測值)

第3章 疾病的背景情況和概要

  • 簡介
  • 風險要素
  • 病因
  • 症狀
  • 病理形成
  • EDSS (神經症狀評估標準)

第4章 流行病學和患者人口

  • 分析的要點
  • 患者人口與預測參數
  • 多發性硬化症的患病人數: (7MM)主要7個國家
  • 多發性硬化症的患病人數: (7MM)主要7個國家,各地區
  • 多發性硬化症的患病人數: (7MM)主要7個國家,分佈結構 (最新值)
  • 多發性硬化症的患病人數: (7MM)主要7個國家,分佈結構 (預測值)

第5章 多發性硬化症的流行病學

第6章 美國

  • 前提條件與合理的理由
  • 多發性硬化症的患病人數
  • 多發性硬化症的患病人數:男女
  • 多發性硬化症的患病人數:各子類型
  • 多發性硬化症的患病人數:各年齡層
  • 多發性硬化症的患病人數:EDSS評分

第7章 德國

第8章 法國

第9章 義大利

第10章 西班牙

第11章 英國

第12章 日本

第13章 未滿足需求

第14章 附錄

第15章 分析方法

  • 資訊來源

第16章 諮詢服務

第17章 免責聲明

第18章 關於DelveInsight

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DIEI0322

DelveInsight's 'Multiple Sclerosis - Epidemiology Forecast to 2027' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Multiple Sclerosis in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

Geography Covered:

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan

Study Period: 2016-2027

Multiple Sclerosis Epidemiology:

The Multiple Sclerosis (MS) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. The epidemiology data for Multiple Sclerosis are studied through all possible division to give a better understanding about the Disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Multiple Sclerosis Epidemiology Segmentation:

The disease epidemiology covered in the report is segmented by Gender [male/female], age group [≤19 years, 20-29 years, 30-39 years, 40-49 years, 50-59 years, 60-69 years, 70-79 years, and ≥80 years], sub-types [Relapsing Remitting MS, Primary Progressive MS and Progressive relapsing MS] and Expanded disability status scale (EDSS) [0.0-1.5, 2.0-3.5, 4.0-5.5, 6.0-7.5 and 8.0-9.5], thus presenting overall detailed analysis of the patient pool characteristics.

The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

According to DelveInsight, the prevalent population of Multiple Sclerosis was estimated to be 1.98 Million [7MM] in 2016 and, is expected to increase at a CAGR of XX% during the study period i.e., 2016-2027. United States accounts for the highest MS Cases, followed by EU5 (Germany, France, Italy, Spain & UK) and Japan. In United States, the peak prevalence has been observed in patients aged 45-49 years in both female and male participants.

Report Scope:

  • The report covers detailed overview of Multiple Sclerosis explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The report provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
  • The Report assesses the disease risk and burden and highlights the unmet needs of Multiple Sclerosis
  • The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report provides the segmentation of the disease epidemiology by gender, age-group, sub-types and EDSS score in 7MM

Key strengths:

  • 10 Year Forecast of Multiple Sclerosis epidemiology
  • 7MM Coverage
  • Total Prevalent Cases of Multiple Sclerosis
  • Prevalent Cases according to segmentation: Gender-specific prevalence, age-specific prevalence, sub-type specific prevalence and prevalence based upon EDSS score

Key assessments:

  • Patient Segmentation
  • Disease Risk & Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Table of Contents

1. Report Introduction

2. Multiple Sclerosis Epidemiology Overview at a Glance

  • 2.1. Prevalent Population of Multiple Sclerosis in 2017
  • 2.2. Prevalent Population of Multiple Sclerosis in 2027

3. Disease Background and Overview: Multiple Sclerosis (MS)

  • 3.1. Introduction
  • 3.2. Risk Factors
  • 3.3. Causes
  • 3.4. Symptoms
  • 3.5. Pathogenesis
  • 3.6. Diagnosis
  • 3.7. Expanded Disability Status Scale (EDSS)

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. Population and Forecast Parameters
  • 4.3. Prevalent Population of Multiple Sclerosis in 7MM
  • 4.4. Prevalent Population of Multiple Sclerosis in 7MM - By Region
  • 4.5. Prevalent Population of Multiple Sclerosis in 7MM - Distribution (2017)
  • 4.6. Prevalent Population of Multiple Sclerosis in 7MM - Distribution (2027)

5. Epidemiology of Multiple Sclerosis

6. United States

  • 6.1. Assumptions and Rationale
  • 6.2. Prevalent Population of Multiple Sclerosis in United States
  • 6.3. Sex-Specific Prevalence of Multiple Sclerosis in United States
  • 6.4. Sub-type Specific Prevalence of Multiple Sclerosis in United States
  • 6.5. Age-Specific Prevalence of Multiple Sclerosis in United States
  • 6.6. Prevalence of Multiple Sclerosis based on EDSS Score in United States

7. Germany

  • 7.1. Assumptions and Rationale
  • 7.2. Prevalent Population of Multiple Sclerosis in Germany
  • 7.3. Sex-Specific Prevalence of Multiple Sclerosis in Germany
  • 7.4. Sub-type Specific Prevalence of Multiple Sclerosis in Germany
  • 7.5. Age-Specific Prevalence of Multiple Sclerosis in Germany
  • 7.6. Prevalence of Multiple Sclerosis based on EDSS Score in Germany

8. France

  • 8.1. Assumptions and Rationale
  • 8.2. Prevalent Population of Multiple Sclerosis in France
  • 8.3. Sex-Specific Prevalence of Multiple Sclerosis in France
  • 8.4. Sub-type Specific Prevalence of Multiple Sclerosis in France
  • 8.5. Age-Specific Prevalence of Multiple Sclerosis in France
  • 8.6. Prevalence of Multiple Sclerosis based on EDSS Score in France

9. Italy

  • 9.1. Assumptions and Rationale
  • 9.2. Prevalent Population of Multiple Sclerosis in Italy
  • 9.3. Sex-Specific Prevalence of Multiple Sclerosis in Italy
  • 9.4. Sub-type Specific Prevalence of Multiple Sclerosis in Italy
  • 9.5. Age-Specific Prevalence of Multiple Sclerosis in Italy
  • 9.6. Prevalence of Multiple Sclerosis based on EDSS Score in Italy

10. Spain

  • 10.1. Assumptions and Rationale
  • 10.2. Prevalent Population of Multiple Sclerosis in Spain
  • 10.3. Sex-Specific Prevalence of Multiple Sclerosis in Spain
  • 10.4. Sub-type Specific Prevalence of Multiple Sclerosis in Spain
  • 10.5. Age-Specific Prevalence of Multiple Sclerosis in France
  • 10.6. Prevalence of Multiple Sclerosis based on EDSS Score in Spain

11. United Kingdom

  • 11.1. Assumptions and Rationale
  • 11.2. Prevalent Population of Multiple Sclerosis in United Kingdom
  • 11.3. Sex-Specific Prevalence of Multiple Sclerosis in United Kingdom
  • 11.4. Sub-type Specific Prevalence of Multiple Sclerosis in United Kingdom
  • 11.5. Age-Specific Prevalence of Multiple Sclerosis in United Kingdom
  • 11.6. Prevalence of Multiple Sclerosis based on EDSS Score in United Kingdom

12. Japan

  • 12.1. Assumptions and Rationale
  • 12.2. Prevalent Population of Multiple Sclerosis in Japan
  • 12.3. Sex-Specific Prevalence of Multiple Sclerosis in Japan
  • 12.4. Sub-type Specific Prevalence of Multiple Sclerosis in Japan
  • 12.5. Age-Specific Prevalence of Multiple Sclerosis in Japan
  • 12.6. Prevalence of Multiple Sclerosis based on EDSS Score in Japan

13. Unmet Needs

14. Appendix

15. Report Methodology

  • 15.1. Sources Used

16. Consulting Services

17. Disclaimer

18. About DelveInsight

List of Tables

  • Table 1: Expanded Disability Status Scale (EDSS)
  • Table 2: Total Prevalent Population of Multiple Sclerosis in 7 MM (2016-2027)
  • Table 3: Prevalent Population of Multiple Sclerosis in 7MM- By Region (2016-2027)
  • Table 4: Prevalent Population of Multiple Sclerosis in United States (2016-2027)
  • Table 5: Sex-Specific Prevalent Population of Multiple Sclerosis in United States (2016-2027)
  • Table 6: Sub-type Specific Prevalent Population of Multiple Sclerosis in United States (2016-2027)
  • Table 7: Age Specific Prevalent Population of Multiple Sclerosis in United States (2016-2027)
  • Table 8: Prevalent Population of Multiple Sclerosis based on EDSS Score in United States (2016-2027)
  • Table 9: Prevalent Population of Multiple Sclerosis in Germany (2016-2027)
  • Table 10: Sex-Specific Prevalent Population of Multiple Sclerosis in Germany (2016-2027)
  • Table 11: Sub-type Specific Prevalent Population of Multiple Sclerosis in Germany (2016-2027)
  • Table 12: Age Specific Prevalent Population of Multiple Sclerosis in Germany (2016-2027)
  • Table 13: Prevalent Population of Multiple Sclerosis based on EDSS Score in Germany (2016-2027)
  • Table 14: Prevalent Population of Multiple Sclerosis in France (2016-2027)
  • Table 15: Sex-Specific Prevalent Population of Multiple Sclerosis in France (2016-2027)
  • Table 16: Sub-type Specific Prevalent Population of Multiple Sclerosis in France (2016-2027)
  • Table 17: Age Specific Prevalent Population of Multiple Sclerosis in France (2016-2027)
  • Table 18: Prevalent Population of Multiple Sclerosis based on EDSS Score in France (2016-2027)
  • Table 19: Prevalent Population of Multiple Sclerosis in Italy (2016-2027)
  • Table 20: Sex-Specific Prevalent Population of Multiple Sclerosis in Italy (2016-2027)
  • Table 21: Sub-type Specific Prevalent Population of Multiple Sclerosis in Italy (2016-2027)
  • Table 22: Age Specific Prevalent Population of Multiple Sclerosis in Italy (2016-2027)
  • Table 23: Prevalent Population of Multiple Sclerosis based on EDSS Score in Italy (2016-2027)
  • Table 24: Prevalent Population of Multiple Sclerosis in Spain (2016-2027)
  • Table 25: Sex-Specific Prevalent Population of Multiple Sclerosis in Spain (2016-2027)
  • Table 26: Sub-type Specific Prevalent Population of Multiple Sclerosis in Spain (2016-2027)
  • Table 27: Age Specific Prevalent Population of Multiple Sclerosis in Spain (2016-2027)
  • Table 28: Prevalent Population of Multiple Sclerosis based on EDSS Score in Spain (2016-2027)
  • Table 29: Prevalent Population of Multiple Sclerosis in United Kingdom (2016-2027)
  • Table 30: Prevalent Population of Multiple Sclerosis in United Kingdom (2016-2027)
  • Table 31: Sub-type Specific Prevalent Population of Multiple Sclerosis in United Kingdom (2016-2027)
  • Table 32: Age Specific Prevalent Population of Multiple Sclerosis in United Kingdom (2016-2027)
  • Table 33: Prevalent Population of Multiple Sclerosis based on EDSS Score in United Kingdom (2016-2027)
  • Table 34: Prevalent Population of Multiple Sclerosis in Japan (2016-2027)
  • Table 35: Sex-Specific Prevalent Population of Multiple Sclerosis in Japan (2016-2027)
  • Table 36: Sub-type Specific Prevalent Population of Multiple Sclerosis in Japan(2016-2027)
  • Table 37: Age Specific Prevalent Population of Multiple Sclerosis in Japan (2016-2027)
  • Table 38: Prevalent Population of Multiple Sclerosis based on EDSS Score in Japan (2016-2027)

List of Figures

  • Figure 1: Types of MS
  • Figure 2: Risk factors associated with MS
  • Figure 3: The immunological complexity of the immune/cytokine network in multiple sclerosis
  • Figure 4: Total Prevalent Population of Multiple Sclerosis in 7 MM (2016-2027)
  • Figure 5: Prevalent Population of Multiple Sclerosis in 7MM- By Region(2016-2027)
  • Figure 6: Prevalent Population of Multiple Sclerosis in United States (2016-2027)
  • Figure 7: Sex- Specific Prevalent Population of Multiple Sclerosis in United States (2016-2027)
  • Figure 8: Sub-type Specific Prevalent Population of Multiple Sclerosis in United States (2016-2027)
  • Figure 9: Age Specific Prevalent Population of Multiple Sclerosis in United States (2016-2027)
  • Figure 10: Prevalent Population of Multiple Sclerosis based on EDSS Score in US (2016-2027)
  • Figure 11: Prevalent Population of Multiple Sclerosis in Germany (2016-2027)
  • Figure 12: Sex- Specific Prevalent Population of Multiple Sclerosis in Germany (2016-2027)
  • Figure 13: Sub-type Specific Prevalent Population of Multiple Sclerosis in Germany (2016-2027)
  • Figure 14: Age Specific Prevalent Population of Multiple Sclerosis in Germany (2016-2027)
  • Figure 15: Prevalent Population of Multiple Sclerosis based on EDSS Score in Germany (2016-2027)
  • Figure 16: Prevalent Population of Multiple Sclerosis in France (2016-2027)
  • Figure 17: Sex- Specific Prevalent Population of Multiple Sclerosis in France (2016-2027)
  • Figure 18: Sub-type Specific Prevalent Population of Multiple Sclerosis in France (2016-2027)
  • Figure 19: Age Specific Prevalent Population of Multiple Sclerosis in France (2016-2027)
  • Figure 20: Prevalent Population of Multiple Sclerosis based on EDSS Score in France (2016-2027)
  • Figure 21: Prevalent Population of Multiple Sclerosis in Italy (2016-2027)
  • Figure 22: Sex- Specific Prevalent Population of Multiple Sclerosis in Italy (2016-2027)
  • Figure 23: Sub-type Specific Prevalent Population of Multiple Sclerosis in Italy (2016-2027)
  • Figure 24: Age Specific Prevalent Population of Multiple Sclerosis in Italy (2016-2027)
  • Figure 25: Prevalent Population of Multiple Sclerosis based on EDSS Score in Italy (2016-2027)
  • Figure 26: Prevalent Population of Multiple Sclerosis in Spain (2016-2027)
  • Figure 27: Sex- Specific Prevalent Population of Multiple Sclerosis in Spain (2016-2027)
  • Figure 28: Sub-type Specific Prevalent Population of Multiple Sclerosis in Spain (2016-2027)
  • Figure 29: Age Specific Prevalent Population of Multiple Sclerosis in Spain (2016-2027)
  • Figure 30: Prevalent Population of Multiple Sclerosis based on EDSS Score in Spain (2016-2027)
  • Figure 31: Prevalent Population of Multiple Sclerosis in United Kingdom (2016-2027)
  • Figure 32: Sex- Specific Prevalent Population of Multiple Sclerosis in United Kingdom (2016-2027)
  • Figure 33: Sub-type Specific Prevalent Population of Multiple Sclerosis in United Kingdom (2016-2027)
  • Figure 34: Age Specific Prevalent Population of Multiple Sclerosis in United Kingdom (2016-2027)
  • Figure 35: Prevalent Population of Multiple Sclerosis based on EDSS Score in UK (2016-2027)
  • Figure 36: Prevalent Population of Multiple Sclerosis in Japan (2016-2027)
  • Figure 37: Sex- Specific Prevalent Population of Multiple Sclerosis in Japan (2016-2027)
  • Figure 38: Sub-type Specific Prevalent Population of Multiple Sclerosis in Japan (2016-2027)
  • Figure 39: Age Specific Prevalent Population of Multiple Sclerosis in Japan (2016-2027)
  • Figure 40: Prevalent Population of Multiple Sclerosis based on EDSS Score in Japan (2016-2027)
Back to Top